Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 337

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 337
---
 in the registration statement in accordance
with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information
on us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed
as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified
by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration
statement from the SEC at the address listed above or from the SEC’s website.

| 171 |

<div align='center'>BIODEXA PHARMACEUTICALS PLC

Index to Unaudited Condensed Consolidated Financial Statements for the Six-Month Periods Ended June 30, 2024 and 2023</div>

| Condensed consolidated unaudited statements of comprehensive income for the six-month periods ended June 30, 2024 and 2023            
 Condensed consolidated unaudited statements of financial position at June 30, 2024 and December 31, 2023                              | Page 
 F-1  
 F-2  |
|:--------------------------------------------------------------------------------------------------------------------------------------|:-----|
| Condensed consolidated unaudited statements of cash flows for the six-month periods ended June 30, 2024 and 2023                      | F-3  |
| Condensed consolidated unaudited statements of changes in equity for the six-month periods ended June 30, 2023 and 2024               | F-5  |
| Notes forming part of the condensed consolidated unaudited interim financial information for the six month period ended June 30, 2024 | F-6  |

| 172 |

<div align='center'>BIODEXA PHARMACEUTICALS PLC

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</div>

|                                                                                                     | Page |
| Report of Independent Registered Public Accounting Firm (Forvis Mazars LLP, London, United Kingdom, 
 PCAOB ID 1401)                                                                                      | F-21 |
| Consolidated statements of comprehensive income for the years ended 31 December 2023, 2022 and 2021 | F-23 |
| Consolidated statements of financial position at 31 December 2023, 2022 and 2021                    | F-24 |
| Consolidated statements of cash flows for the years ended 31 December 2023, 2022 and 2021           | F